SCHEMBL3780109

SCHEMBL3780109

Nc1nc(-n2ccnc2)c2nc[nH]c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
LMNA P02545 3/20 0.36
MAPT P10636 1/20 0.36
HRH4 Q9H3N8 2/20 0.35
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
GRIA1 P42261 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA3 P42263 1/20 0.33
GRIA4 P48058 1/20 0.33
CD38 P28907 3/20 0.32
IDO1 P14902 1/20 0.31
CYP3A4 P08684 4/20 0.31
CYP1A2 P05177 3/20 0.31
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
KMT2A Q03164 1/20 0.31
HIF1A Q16665 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3799223 0.82 NOTUM (0.36) LMNAMKNK1MKNK2GRIA1GRIA2
SCHEMBL27324270 0.81 HRH4 (0.33) HRH4
SCHEMBL3773140 0.81 HRH4 (0.33) HRH4
SCHEMBL3768067 0.80 ALDH1A1 (0.41) LMNAMAPTCD38CYP3A4CYP1A2
SCHEMBL3780112 0.77 HRH4 (0.51) LMNAHRH4CYP3A4CYP1A2TSHR
SCHEMBL17364330 0.77 ADORA2A (0.40) ADORA2AADORA1HRH4
SCHEMBL3786825 0.75 CD38 (0.36) CD38CYP3A4CYP1A2KMT2ACLK4
SCHEMBL8826198 0.71 HRH4 (0.50) LMNAHRH4MAPK1
SCHEMBL8830247 0.71 CHUK (0.48) LMNAHRH4MAPK1
SCHEMBL8830437 0.70 CHUK (0.50) LMNAHRH4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855285-B2 Methods for selective N-9 glycosylation of purines BRIGHAM YOUNG UNIVERSITY (US) 2010-12-21 US disclosed
US-20080207891-A1 Methods For Selective N-9 Glycosylation of Purines BRIGHAM YOUNG UNIVERSITY (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207891-A1 Methods For Selective N-9 Glycosylation of Purines PNP, SLC29A2, SLC28A2 ADORA2A 44/4885ADORA1 138/4885LMNA 2535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.